Ethica Corporate Finance advised the shareholders of Doppel Farmaceutici in the sale to the private equity fund Trilantic Capital Partners Europe
Ethica Corporate Finance advised the shareholders of Doppel Farmaceutici in the sale of 90% of the company to the British private equity fund Trilantic Capital Partners Europe.
Founded in 1994, Doppel Farmaceutici is the leading Italian operator in the field of research, development, formulation and packaging of medicines for third parties.
Since 2003, Doppel Farmaceutici is also active in the production, for third parties, of food supplements, nutraceuticals and medical devices.
Giacinto d’Onofrio, partner of Trilantic Capital Partners Europe commented: “Doppel Farmaceutici is an already excellent company, we will help it in international growth, with the aim of creating a leading company in Europe in a rapidly growing sector, which we deeply analysed”.